Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Regeneron Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 59.71B | 13.6x | 1.31 | USD 558.16 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Lonza Group AG | OTC Markets | Healthcare | Biotechnology & Medical Research | USD 46.75B | 58x | USD 65.86 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.9% Upside | Upgrade to Pro+ | ||
argenx ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 36.55B | 43.1x | 0.12 | USD 605.90 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.2% Upside | Upgrade to Pro+ | |
IQVIA Holdings | NYSE | Healthcare | Biotechnology & Medical Research | USD 26.35B | 19.8x | 6.81 | USD 149.15 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BeiGene ADS | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 26.15B | -44.4x | -1.4 | USD 238.84 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37.9% Upside | Upgrade to Pro+ | |
BioNTech | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 23.76B | -31.3x | 0.18 | USD 99 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.7% Upside | Upgrade to Pro+ | |
Summit Therapeutics PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 19.28B | -59.7x | -1.13 | USD 24.63 | -5.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.2% Upside | Upgrade to Pro+ | |
Insmed | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 12.86B | -12.6x | 3.15 | USD 71.01 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.2% Upside | Upgrade to Pro+ | |
Genmab AS | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 12.43B | 10.6x | 0.12 | USD 19.51 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.5% Upside | Upgrade to Pro+ | |
ICON PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 11.72B | 15.1x | 0.51 | USD 145.17 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 45.7% Upside | Upgrade to Pro+ | |
WuXi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | USD 11.06B | 31.2x | 31.43 | USD 2.74 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
WuXi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | USD 11.06B | 31.2x | 31.43 | USD 5.42 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Exelixis | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 10.24B | 20.2x | 0.11 | USD 36.53 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.8% Upside | Upgrade to Pro+ | |
Moderna | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 10.11B | -2.8x | -0.11 | USD 26.26 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 48.5% Upside | Upgrade to Pro+ | |
Ascendis Pharma AS | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 9.31B | -22.1x | -0.89 | USD 153.85 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36% Upside | Upgrade to Pro+ | |
Medpace Holdings | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 9.27B | 23.2x | 0.53 | USD 305.11 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.2% Upside | Upgrade to Pro+ | |
Qiagen | NYSE | Healthcare | Biotechnology & Medical Research | USD 8.98B | 106.6x | -1.43 | USD 41.53 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.2% Upside | Upgrade to Pro+ | |
Bio-Techne | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 8.09B | 50.9x | -1.71 | USD 51.07 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
EXACT Sciences | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 8.06B | -7.7x | 0.02 | USD 43.68 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 45.7% Upside | Upgrade to Pro+ | |
Tempus AI | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 7.46B | -7.8x | 0.2 | USD 42.93 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Madrigal Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 7.07B | -14.5x | 1.58 | USD 320.33 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.4% Upside | Upgrade to Pro+ | |
Revolution Med | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 6.71B | -10.1x | -1.53 | USD 36.33 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Legend Bio | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 6.21B | -34.7x | -0.49 | USD 33.72 | 5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Telix Pharmaceuticals ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 5.65B | 190.5x | 0.22 | USD 16.82 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37.4% Upside | Upgrade to Pro+ | |
Charles River Laboratories | NYSE | Healthcare | Biotechnology & Medical Research | USD 5.19B | 529.3x | -4.86 | USD 105.92 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Blueprint Medicines Corp | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 5.19B | -75.6x | -0.88 | USD 81.27 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Nuvalent | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 5.04B | -17.6x | 0.22 | USD 70.85 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Verona Pharma ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 4.91B | -30.5x | 0.14 | USD 58.47 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36% Upside | Upgrade to Pro+ | |
Krystal Biotech | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 4.86B | 53.4x | 0.08 | USD 169.13 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30% Upside | Upgrade to Pro+ | |
Cytokinetics Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 4.56B | -7.3x | -2.26 | USD 38.56 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alkermes Plc | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 4.54B | 12.4x | 3.4 | USD 27.94 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.6% Upside | Upgrade to Pro+ | |
Ionis Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 4.51B | -9.3x | 0.52 | USD 28.40 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
PureTech Health | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 4.01B | -55.6x | 0.06 | USD 16.81 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Vaxcyte | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 3.89B | -7.9x | -1.06 | USD 30.24 | -5.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Crispr Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 3.34B | -9x | 0.07 | USD 38.98 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Arcellx | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 3.31B | -32.3x | 0.84 | USD 61.49 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Soleno Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 3.21B | -15.8x | 0.21 | USD 70.25 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47.3% Upside | Upgrade to Pro+ | |
Akero Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 3.03B | -10.1x | 0.37 | USD 38.08 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merus | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 2.99B | -12.7x | 1.15 | USD 43.22 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Protagonist Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 2.88B | 10.5x | 0.02 | USD 46.95 | 4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47% Upside | Upgrade to Pro+ | |
Scholar Rock | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 2.87B | -11.8x | 0.53 | USD 30.22 | 4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Crinetics Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 2.75B | -8x | USD 29.68 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Immunovant | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 2.63B | -5.8x | 0.15 | USD 15.47 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Viking Therapeutics Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 2.61B | -22.8x | 2.11 | USD 23.09 | -6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alvotech | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 2.57B | -11.2x | -0.18 | USD 8.60 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Xenon Pharmaceuticals | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 2.54B | -11.1x | 0.99 | USD 33.03 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ACADIA | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 2.50B | 10.9x | 0.02 | USD 14.99 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Veracyte Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 2.46B | 98.4x | 0.79 | USD 31.76 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.1% Upside | Upgrade to Pro+ | |
Immunitybio Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 2.37B | -4.7x | -0.12 | USD 2.77 | -4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
MoonLake Immunotherapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | USD 2.33B | -19.2x | 0.12 | USD 36.77 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |